172751-17-6

Basic information

• Product Name: 2,4(1H,3H)-Pyrimidinedione, 5,6-diamino-1-(phenylmethyl)-
• CAS NO: 172751-17-6
• Molecular Formula: C11H12N4O2
• Molecular Weight: 232.242
• Mol File: 172751-17-6.mol
• Article Data: 17

Chemical Properties

• CAS DataBase Reference: 2,4(1H,3H)-Pyrimidinedione, 5,6-diamino-1-(phenylmethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4(1H,3H)-Pyrimidinedione, 5,6-diamino-1-(phenylmethyl)-(172751-17-6)
• EPA Substance Registry System: 2,4(1H,3H)-Pyrimidinedione, 5,6-diamino-1-(phenylmethyl)-(172751-17-6)

Safety Data

• Hazardous Substances Data: 172751-17-6(Hazardous Substances Data)

Usage

General Description

2,4(1H,3H)-Pyrimidinedione, 5,6-diamino-1-(phenylmethyl)-, also known as dapagliflozin, is a pharmaceutical compound that belongs to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors. It is used in the treatment of type 2 diabetes to help control blood sugar levels. Dapagliflozin works by inhibiting the reabsorption of glucose in the kidneys, leading to increased urinary excretion of glucose and lowering blood sugar levels. It has been approved for use in several countries and is often prescribed as part of a comprehensive treatment plan for individuals with type 2 diabetes.

Upstream product

• 538-32-9 benzylurea 
• 41862-11-7 1-benzyl-6-aminouracil 
• 5770-23-0 6-amino-5-nitroso-1-(phenylmethyl)-2,4(1H,3H)-pyrimidinedione 

Downstream Products

• 64344-86-1 1-benzyllumazine 
• 19844-93-0 3,9-dihydro-3-(phenylmethyl)-1H-purine-2,6-dione 
• 1313389-01-3 3-benzyl-8-(1,5-dimethyl-1H-pyrazol-3-yl)-1H-purine-2,6(3H,7H)-dione 
• 1313388-95-2 3-benzyl-8-(1,3-dimethyl-1H-pyrazol-5-yl)-1H-purine-2,6(3H,7H)-dione 
• 1415031-03-6 C₁₇H₁₆N₄O₄S 
• 200556-91-8 3-benzyl-8-cyclopentyl-1H-purine-2,6(3H,7H)-dione 
• 1313388-86-1 (S)-4-benzyl-8-ethyl-7,8-dihydro-2-(1,3-dimethyl-1H-pyrazol-5-yl)-1H-imidazo[2,1-i]purin-5(4H)-one 
• 1313388-50-9 (R,S)-6-(1-hydroxypropan-2-ylamino)-3-benzyl-8-(3-(benzyloxy)-1-methyl-1H-pyrazol-5-yl)-3H-purin-2(7H)-one 
• 1313388-85-0 (R)-4-benzyl-8-ethyl-7,8-dihydro-2-(1,3-dimethyl-1H-pyrazol-5-yl)-1H-imidazo[2,1-i]purin-5(4H)-one 
• 1313388-46-3 (R,S)-6-(1-hydroxybutan-2-ylamino)-3-benzyl-8-(3-methoxy-1-methyl-1H-pyrazol-5-yl)-3H-purin-2(7H)-one 

Relevant articles and documents

Synthesis and Pharmacological Evaluation of Identified and Putative Metabolites of the A1 Adenosine Receptor Antagonist 8-Cyclopentyl-3-(3-fluoropropyl)-1-propylxanthine (CPFPX)

The A1 adenosine receptor (A1AR) antagonist [18F]8-cyclopentyl-3-(3-fluoropropyl)-1-propylxanthine ([18F]CPFPX), used in imaging human brain A1ARs by positron emission tomography (PET), is stable in t

Allosteric competitive inhibitors of the glucose-1-phosphate thymidylyltransferase (RmlA) from pseudomonas aeruginosa

Glucose-1-phosphate thymidylyltransferase (RmlA) catalyzes the condensation of glucose-1-phosphate (G1P) with deoxy-thymidine triphosphate (dTTP) to yield dTDP-d-glucose and pyrophosphate. This is the first step in the l-rhamnose biosynthetic pathway. l-R

Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4)

The tyrosine kinase EphB4 is an attractive target for drug design because of its recognized role in cancer-related angiogenesis. Recently, a series of commercially available xanthine derivatives were identified as micromolar inhibitors of EphB4 by high-throughput fragment-based docking into the ATP-binding site of the kinase domain. Here, we have exploited the binding mode obtained by automatic docking for the optimization of these EphB4 inhibitors by chemical synthesis. Addition of only two heavy atoms, methyl and hydroxyl groups, to compound 4 has yielded the single-digit nanomolar inhibitor 66, with a remarkable improvement of the ligand efficiency from 0.26 to 0.37 kcal/(mol per non-hydrogen atom). Compound 66 shows very high affinity for a few other tyrosine kinases with threonine as gatekeeper residue (Abl, Lck, and Src). On the other hand, it is selective against kinases with a larger gatekeeper. A 45 ns molecular dynamics (MD) simulation of the complex of EphB4 and compound 66 provides further validation of the binding mode obtained by fragment-based docking. 2009 American Chemical Society.